0L8L.L - Spark Therapeutics, Inc.

LSE - LSE Delayed price. Currency in USD
114.50
+41.41 (+56.66%)
At close: 4:32PM GMT
Stock chart is not supported by your current browser
Previous close73.09
Open114.50
Bid0.00 x 0
Ask0.00 x 0
Day's range114.50 - 114.50
52-week range114.50 - 114.50
Volume74,458
Avg. volumeN/A
Market capN/A
Beta (5Y monthly)N/A
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • FTC staff recommends approval of Roche deal for Spark - report
    Reuters

    FTC staff recommends approval of Roche deal for Spark - report

    The Federal Trade Commission staff reviewing Roche's <RBO.PA> plan to buy U.S.-based gene therapy specialist Spark Therapeutics <ONCE.O> for $4.3 billion (£3.34 billion) recommended that the deal be approved without requiring any asset sales, the Capitol Forum reported on Thursday. Basel-based Roche, the biggest maker of cancer drugs, said in February that it would buy the U.S. company, acquiring a portfolio that includes a blindness treatment that has U.S. and European approval and other projects for neurodegenerative disorders like Huntington's disease. One of its projects is a gene therapy treatment for hemophilia.

  • Roche lifts 2019 sales view again as Chinese demand soars
    Reuters

    Roche lifts 2019 sales view again as Chinese demand soars

    Swiss drugmaker Roche lifted its 2019 sales target on Wednesday for the third time this year, helped by newer medicines and as China bought more cancer drugs to treat a disease blamed for a quarter of the nation's annual deaths. Roche's full-year revenue is now seen growing at a high-single-digit percentage rate, the Basel-based company said, to what would easily top $60 billion. The new forecast sets a high bar for Swiss rival Novartis, which reports results next week.

  • Roche CEO touts drugs pipeline, rules out M&A just to boost sales
    Reuters

    Roche CEO touts drugs pipeline, rules out M&A just to boost sales

    Swiss drugmaker Roche <ROG.S> sees medicines in its own pipeline driving sales growth over the longer term, Chief Executive Severin Schwan told Reuters on Friday, adding he will not pursue takeovers simply to keep revenue rising. In an interview at Roche's Basel headquarters, Schwan also said ongoing U.S. Federal Trade Commission (FTC) scrutiny of Roche's $4.3 billion takeover of Spark Therapeutics <ONCE.O> came as a surprise, forcing delays. Roche has twice upgraded 2019 sales forecasts, the latest time to mid- to high-single-digit percentage rate growth, as medicines including Ocrevus for multiple sclerosis and Hemlibra for haemophilia A offset incursions by rivals' copies of its $22 billion-per-year cancer trio Herceptin, Rituxan and Avastin.

  • Companies to Watch: Roche gets more time for Spark deal, AstraZeneca shows promise in clinical trial, Snap get upgraded
    Yahoo Finance

    Companies to Watch: Roche gets more time for Spark deal, AstraZeneca shows promise in clinical trial, Snap get upgraded

    Roche, Spark, AstraZeneca, Snap, Walmart and eBay are the companies to watch

  • Roche, Spark again extend $4.3 billion takeover offer
    Reuters

    Roche, Spark again extend $4.3 billion takeover offer

    Roche Holding and Spark Therapeutics announced on Tuesday another extension of the Swiss drugmaker's $4.3 billion takeover offer for the U.S. gene therapy specialist as regulatory reviews continue. The offer for Spark shares now runs to Oct. 1, Roche said. Around 24.1% of Spark's outstanding shares had been tendered as of the end of August.

  • Roche's $4.3 billion Spark bid delayed again amid U.S., UK scrutiny
    Reuters

    Roche's $4.3 billion Spark bid delayed again amid U.S., UK scrutiny

    Swiss drugmaker Roche's $4.3 billion takeover of U.S. gene therapy specialist Spark Therapeutics has been pushed back again, possibly beyond the first half, as regulators continue to scrutinize the deal for its effect on competition. Roche said on Monday that both companies received a request for more information from the U.S. Federal Trade Commission in connection with the FTC's review of the deal, sending Spark shares down nearly 15% at $93 in premarket trading on Monday. Roche also said that the UK Competition and Markets Authority (CMA) has opened an investigation.

By using Yahoo, you agree that we and our partners can use cookies for purposes such as customising content and advertising. See our Privacy Policy to learn more